Business
Prelim Results and publication of Annual Report
Allergy Therapeutics plc reported stable financial performance for the year ended June 30, 2025, with revenue of £55.0 million, broadly flat compared to the previous year, though constant currency revenue grew over 2%. The company experienced an operating loss of £28.2 million, an improvement from £35.3 million in 2024, and an Adjusted EBITDA loss of £9.0 million. Significant post-period events include the full repayment of shareholder loan liabilities and the securing of a new £50 million unsecured shareholder loan facility, alongside continued progress in R&D programs and exploration of a dual primary listing in Hong Kong. Disclaimer*
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\" or the \"Company\")\n \nAudited Preliminary Results and publication of Annual Report for the Year ended 30 June 2025\n \n- Stable financial performance with selective investment in strategic growth-related projects.\n \n- Well placed for future growth as the German market transitions to fully licensed products with the end of the TAV period.\n \n- Strengthened balance sheet post-period through full repayment of shareholder loan liabilities and securing a new £50m unsecured uncommitted shareholder loan facility.\n \n- Continued progress across late-stage R&D programmes, including regulatory advancement for Grass MATA MPL and encouraging clinical data from the VLP Peanut PROTECT trial.\n \n- Improving commercial momentum supported by increased demand for registered products.\n \n- Post-period, commenced exploration of dual primary listing of ordinary shares in Hong Kong.\n \n- Annual Report for the Year ended 30 June 2025 available electronically on the Company's website at www.allergytherapeutics.com\n \n11 December 2025 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces its audited preliminary results for the year ended 30 June 2025.\n \nHighlights\n \nFinancial\n- Revenue of £55.0m (2024: £55.2m) from the Group's commercial portfolio remained broadly flat, reflecting the earlier than expected impact of the approaching end of the TAV transition period in Germany and the shift to fully licensed products. On a constant currency basis*, revenue grew by over 2 percent.\n \n- Continuing cost controls during the year have helped to manage the cost base of the Group while enabling selective investment in strategic growth-related projects. Operating loss was £28.2m (2024: £35.3m loss). Adjusted EBITDA** was a loss of £9.0m (2024: £7.6m loss), reflecting flat revenue performance combined with strategic investments to support future growth.\n \n- &nb...